PUR0110
Pre-clinical- Indications
- Inflammation
Company intelligence / Profile preview
PurGenesis Technologies Inc. develops botanical pharmaceuticals and cosmeceuticals using proprietary extraction technology. Its lead pharmaceutical program, PUR0110/Thykamine™, has shown positive results in Phase II trials for atopic dermatitis and ulcerative colitis with a strong safety profile. The company also markets the award-winning Purgenesis™ anti-aging skincare line containing the patented R-Spinasome® antioxidant complex, recognized by the Canadian Dermatology Association’s Skin Health Program.[2][3][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PurGenesis Technologies Inc..